Proposal for AMG 487 (CXCR3 antagonist)

Overview of Therapeutic Candidate:
AMG 487 is a synthetic small‐molecule antagonist that belongs to the quinazolinone (specifically, the 8-azaquinazolinone) class of compounds, which were identified through high-throughput screening approaches and subsequent medicinal chemistry optimization. AMG 487 was discovered by Chemocentryx and later licensed to Amgen, and it has been developed to target CXCR3, a G protein-coupled receptor (GPCR) important in mediating immune cell trafficking and inflammatory responses. As a representative of the chemokine receptor antagonist class, AMG 487 is similar to other small molecules that disrupt ligand–receptor interactions, thereby modulating immune responses. Traditionally, this class of compounds has been explored for their role in attenuating immune cell migration in inflammatory and autoimmune disease models, as well as cancer metastasis, with AMG 487 being the only small molecule CXCR3 antagonist to reach clinical evaluation in conditions such as psoriasis (Pease, 2017; Medina, Johnson, & Collins, 2005). Its chemical synthesis follows conventional routes for development of heterocyclic compounds, leading to high potency due to an optimized structure that yields low nanomolar inhibition of CXCR3 binding to its natural chemokine ligands.

Therapeutic History:
AMG 487 has been studied extensively in the context of inflammation and cancer. Preclinically, it demonstrated potent efficacy in blocking CXCR3-mediated leukocyte migration and reducing inflammatory cell infiltration in animal models. For example, in mouse models of lung inflammation, AMG 487 effectively attenuated leukocyte recruitment induced by CXCR3 ligands and mimicked the phenotype of CXCR3-deficient mice (Pease & Horuk, 2009). In oncology, particularly in models of breast cancer metastasis, AMG 487 was used to pre-treat tumor cells, reducing their metastatic capacity without affecting basic cell proliferation (Walser et al., 2006). Clinically, AMG 487 advanced into Phase IIa trials for psoriasis, a disease where CXCR3-driven T-cell infiltration is a prominent feature; however, it ultimately failed to demonstrate robust efficacy in that indication (Pease, 2017; Andrews & Cox, 2016). Despite its investigative use in these conditions, AMG 487 has not been evaluated in celiac disease specifically, and a search of ClinicalTrials.gov returned no results (ClinicalTrials.gov, n.d.). Nevertheless, the preclinical data in inflammatory models and the recognized role of CXCR3 in driving immune cell recruitment provide a mechanistic rationale for the repurposing of AMG 487 for celiac disease, particularly given the evidence linking CXCR3 to gliadin-induced zonulin release and enterocyte dysfunction in celiac pathology (Lammers et al., 2008; Medina, Johnson, & Collins, 2005).

Mechanism of Action:
CXCR3 is a chemokine receptor that binds the ligands CXCL9, CXCL10, and CXCL11, which are typically upregulated by interferon-gamma during inflammatory responses. When these ligands bind to CXCR3 expressed on T cells, and notably on the luminal surface of enterocytes in the intestine, they initiate a signaling cascade that involves coupling to G proteins and subsequent recruitment of the adaptor protein MyD88. This signaling cascade has been implicated in the release of zonulin, a protein that modulates the assembly of tight junctions and thus regulates paracellular permeability (Lammers et al., 2008; Monzani, 2022). AMG 487 functions as a competitive antagonist by binding to the CXCR3 receptor with high affinity (IC₅₀ ~8 nM) and blocking the interaction of its natural ligands. In doing so, AMG 487 prevents the receptor from activating downstream G protein-coupled pathways, thereby abrogating the recruitment of MyD88 that normally occurs in response to gliadin peptides. This blockade is expected to inhibit the subsequent zonulin release, ultimately preserving the integrity of tight junctions between enterocytes. At the molecular level, the antagonist binding site is located within the transmembrane region of CXCR3, which is critical for its ability to transduce signals upon chemokine binding (Pease, 2017; Nedjai et al., 2015). The metabolic and pharmacokinetic properties of AMG 487—such as its oral bioavailability and the generation of active metabolites—further complement its mode of action by ensuring that sufficient antagonist concentrations can be achieved systemically to block CXCR3 effectively (Mladic et al., 2015; Pease, 2017).

Expected Effect:
Based on the central hypothesis, blocking the CXCR3 receptor on enterocytes with AMG 487 is anticipated to interrupt the pathological signaling cascade induced by gliadin peptides in celiac disease. In assay systems such as gliadin-challenge organoid cultures, AMG 487 should prevent the recruitment of MyD88 downstream of CXCR3 activation. This inhibition is expected to block the release of zonulin, thereby preserving the localization and function of tight junction proteins such as zonula occludens-1 (ZO-1) and occludin. The preservation of these tight junction components would maintain transepithelial electrical resistance (TEER) and reduce FITC-dextran flux, which are standard measures of barrier integrity (Lammers et al., 2008; Monzani, 2022; Khaleghi et al., 2016). In this assay, enterocytes or intestinal organoids treated with gliadin peptides typically exhibit increased paracellular permeability due to zonulin release; however, if AMG 487 is effective, the expected outcome would be a marked reduction in zonulin secretion and a corresponding maintenance of tight junction organization. This, in turn, would lead to improved intestinal barrier function, reducing the translocation of immunogenic gluten peptides. Since CXCR3 expression is increased in the intestinal mucosa of active celiac disease patients and is linked to the pathological cascade triggered by gliadin, the inhibition of CXCR3 by AMG 487 could indirectly reduce mucosal inflammation and immune cell recruitment. Such effects would be particularly important in a disease where even subtle defects in barrier integrity can lead to significant immune activation and tissue damage (Monzani, 2022; Khaleghi et al., 2016; Machado, 2023).

Overall Evaluation:
The therapeutic candidate AMG 487 presents several compelling strengths for repurposing in the treatment of celiac disease. One of its major strengths is its high potency as a CXCR3 antagonist, with documented low nanomolar inhibitory concentrations on receptor–ligand interactions (Pease, 2017; Medina, Johnson, & Collins, 2005). This potency is crucial given that effective blockade of the CXCR3 receptor is necessary to prevent the gliadin-induced signaling cascade that leads to zonulin release and tight junction disruption. Moreover, the fact that AMG 487 has been previously evaluated in clinical trials (albeit in psoriasis) provides an important foundation for its safety and tolerability in humans (Pease, 2017; Andrews & Cox, 2016). Its oral bioavailability further enhances its appeal, as an orally administered agent is highly desirable for chronic conditions like celiac disease, where long-term treatment compliance is key (Pease, 2017; Mladic et al., 2015).

Biochemically, the mechanism of CXCR3 antagonism is well validated by both preclinical and biochemical studies. The receptor is known to play a critical role in mediating gliadin-induced zonulin release via MyD88-dependent signaling, which is directly linked to tight junction disassembly in enterocytes (Lammers et al., 2008; Monzani, 2022). By blocking this pathway, AMG 487 theoretically has the potential to maintain intestinal barrier integrity and reduce paracellular permeability—a finding that would be highly advantageous in the management of celiac disease. Furthermore, preclinical animal models and in vitro assays in other inflammatory contexts have demonstrated the efficacy of CXCR3 antagonists in reducing immune cell migration and inflammatory responses (Pease & Horuk, 2009; Walser et al., 2006).

However, there are also notable weaknesses and uncertainties regarding the application of AMG 487 to celiac disease. Despite its promising profile in other disease models, AMG 487 has not been directly evaluated in clinically relevant celiac disease models, and no trial data exist from either clinical trials or robust preclinical studies in this specific indication (ClinicalTrials.gov, n.d.). The mechanistic hypothesis, while logical, extrapolates from the known role of CXCR3 in gliadin-induced signaling; however, enterocyte-specific effects and the complex interplay of zonulin release and tight junction regulation in the context of a gluten challenge remain to be rigorously demonstrated. Additionally, prior clinical studies in psoriasis have shown that despite favorable pharmacokinetics and safety data, the compound did not meet efficacy endpoints, which may raise questions about its overall effectiveness in modulating immune responses in chronic inflammatory conditions (Pease, 2017; Andrews & Cox, 2016). Furthermore, potential issues related to metabolic liabilities—such as the formation of reactive metabolites and interactions with CYP3A4—could complicate dosing and long-term safety in a patient population that might require chronic therapy (Mladic et al., 2015; Pease, 2017).

Nonetheless, the approach of targeting the CXCR3 pathway represents an innovative therapeutic strategy that directly addresses a key pathogenic mechanism in celiac disease—the disruption of intestinal barrier function due to zonulin release. As our understanding of the molecular underpinnings of celiac disease deepens, particularly in relation to the CXCR3–MyD88 signaling axis in enterocytes, AMG 487 offers a targeted intervention that could complement existing treatments based on gluten avoidance and barrier preservation (Lammers et al., 2008; Machado, 2023; Khaleghi et al., 2016).

In conclusion, while AMG 487 is not yet proven in the context of celiac disease, its well-characterized mechanism, favorable oral bioavailability, and prior human safety data position it as a promising candidate worth pursuing in exploratory preclinical models of celiac disease. Critical next steps include the execution of gliadin-challenge organoid assays and animal models that recapitulate the celiac pathology, with careful attention to measuring endpoints such as zonulin secretion, TEER, and tight junction protein localization. Should these studies yield positive results, subsequent clinical evaluation in celiac patients would be warranted. Overall, AMG 487 represents a scientifically sound and innovative approach to modulating a key pathogenic process in celiac disease; however, further dedicated studies are required to confirm its efficacy and safety in this new therapeutic context (Pease, 2017; Monzani, 2022; ClinicalTrials.gov, n.d.).

References
Andrews, S. P., & Cox, R. J. (2016). Small molecule CXCR3 antagonists. Journal of Medicinal Chemistry, 59(7), 2894–2917. https://doi.org/10.1021/acs.jmedchem.5b01337

ClinicalTrials.gov. (n.d.). Search for AMG 487 CXCR3 antagonist celiac disease. https://clinicaltrials.gov

Khaleghi, S., Ju, J. M., Lamba, A., & Murray, J. A. (2016). The potential utility of tight junction regulation in celiac disease: Focus on larazotide acetate. Therapeutic Advances in Gastroenterology, 9, 37–49. https://doi.org/10.1177/1756283X15616576

Lammers, K. M., Lu, R., Brownley, J., Lu, B., Gerard, C., Thomas, K., Rallabhandi, P., Shea-Donohue, T., Tamiz, A., Alkan, S., Netzel–Arnett, S., Antalis, T., Vogel, S. N., & Fasano, A. (2008). Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology, 135, 194–204.e3. https://doi.org/10.1053/j.gastro.2008.03.023

Machado, M. V. (2023). New developments in celiac disease treatment. International Journal of Molecular Sciences, 24, 945. https://doi.org/10.3390/ijms24020945

Medina, J. C., Johnson, M. G., & Collins, T. L. (2005). CXCR3 antagonists. Annual Reports in Medicinal Chemistry, 40, 215–225. https://doi.org/10.1016/S0065-7743(05)40014-7

Mladic, M., Scholten, D. J., Wijtmans, M., Falck, D., Leurs, R., Niessen, W. M. A., Smit, M. J., & Kool, J. (2015). Metabolic profiling of ligands for the chemokine receptor CXCR3 by liquid chromatography-mass spectrometry coupled to bioaffinity assessment. Analytical and Bioanalytical Chemistry, 407, 7067–7081. https://doi.org/10.1007/s00216-015-8867-z

Monzani, R. (2022). Role of ER stress in the pathogenesis of celiac disease. Journal name unknown.

Nedjai, B., Viney, J. M., Li, H., Hull, C., Anderson, C. A., Horie, T., Horuk, R., Vaidehi, N., & Pease, J. E. (2015). CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779. British Journal of Pharmacology, 172, 1822–1833. https://doi.org/10.1111/bph.13027

Pease, J. E. (2017). Designing small molecule CXCR3 antagonists. Expert Opinion on Drug Discovery, 12, 159–168. https://doi.org/10.1080/17460441.2017.1268597

Pease, J. E., & Horuk, R. (2009). Chemokine receptor antagonists: Part 2. Expert Opinion on Therapeutic Patents, 19, 199–221. https://doi.org/10.1517/13543770802641353

Walser, T. C., Rifat, S., Ma, X., Kundu, N., Ward, C., Goloubeva, O., Johnson, M. G., Medina, J. C., Collins, T. L., & Fulton, A. M. (2006). Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Research, 66, 7701–7707. https://doi.org/10.1158/0008-5472.CAN-06-0709
